Clinical Trial Update: A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase I trial of JS004, a recombinant humanized anti-BTLA monoclonal antibody, in combination with toripalimab for advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastric Adenocarcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• JS004 (JS004)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer | Phase 1 | Status: TERMINATED